Aberrant amplification and/or overexpression of MYCN is not only observed in NEPC, but also in other aggressive tumors, such as neuroblastoma, medulloblastoma, retinoblastoma, small cell carcinoma of the lung, pancreatic neuroendocrine tumors, and glioblastoma to name a few [14,15,16]. Here, MYCN is linked to neuroblastoma.